3 Undervalued Healthcare Stocks With High Potential

NYSE: ABBV | AbbVie Inc.  News, Ratings, and Charts

ABBV – The healthcare sector is expected to grow rapidly due to the growing need for precision drugs, the rising elderly population, government initiatives, and increasing chronic diseases. Against this backdrop, investors could consider buying fundamentally strong, undervalued healthcare stocks such as AbbVie (ABBV), Bristol-Myers Squibb (BMY), and Gilead Sciences (GILD). Read on…

The healthcare industry’s growth is driven by the fast-rising medical needs, the growing demand for personalized and precision drugs, and the use of advanced technologies.

Given this backdrop, investors could consider buying undervalued healthcare stocks such as AbbVie Inc. (ABBV), Bristol-Myers Squibb Company (BMY), and Gilead Sciences, Inc. (GILD), given their high potential. Before diving deeper into the fundamentals of these stocks, let’s discuss what’s shaping the healthcare industry’s prospects.

The healthcare industry is not cyclical given the consistent demand for medications and treatments. The increasing incidence of chronic diseases like diabetes, arthritis, and cancer, an aging population, and global initiatives to improve drug affordability and accessibility are expected to boost the need for effective drugs and therapies.

Additionally, expansion into new markets and obtaining approval for innovative medications present opportunities for expansion. Advanced technologies such as AI, IoT, and big data analytics have revolutionized drug discovery and manufacturing, accelerated clinical trial timelines, and enhanced supply chain efficiency.

Furthermore, the growing demand for tailored treatments to improve clinical efficacy drives the demand for personalized and precision medicine. The U.S. pharmaceutical market is projected to reach $760 million by 2030, growing at a CAGR of 5.5%.

In light of these encouraging trends, let’s examine the fundamentals of the three healthcare sector stock picks.

AbbVie Inc. (ABBV)

ABBV discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, Skyrizi, Rinvoq, Imbruvica, Epkinly, Elahere, and Venclexta/Venclyxto.

On June 4, 2024, ABBV announced that RINVOQ is indicated in the U.S. for treating pediatric patients aged two and older with active polyarticular juvenile idiopathic arthritis and psoriatic arthritis. RINVOQ LQ, a weight-based oral solution for pediatric patients, is also available.

In terms of forward EV/EBIT, ABBV is trading at 14x, 12.5% lower than the industry average of 15.99x. Its 15.17x forward non-GAAP P/E is 22.8% lower than the 19.64x industry average.

ABBV’s net revenues for the fiscal first quarter that ended March 31, 2024, increased marginally year-over-year to $12.31 billion. Its operating earnings rose marginally over the prior-year quarter to $2.80 billion. In addition, its adjusted earnings after tax stood at $4.12 billion. Also, its adjusted EPS came in at $2.31.

Analysts expect ABBV’s revenue and EPS for the quarter ending June 30, 2024, to increase 1% and 4.9% year-over-year to $14.01 billion and $3.05, respectively. The company surpassed the Street revenue estimates in each of the trailing four quarters, which is impressive. Over the past year, the stock has gained 23.4%, closing the last trading session at $170.46.

ABBV’s POWR Ratings reflect this positive outlook. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system. The POWR Ratings are calculated by considering 118 distinct factors, with each factor weighted to an optimal degree.

ABBV has a B grade for Growth, Value, and Quality. It is ranked #6 out of 155 stocks in the Medical – Pharmaceuticals industry. Click here to see ABBV’s Momentum, Stability, and Sentiment ratings.

Bristol-Myers Squibb Company (BMY)

BMY discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases.

On May 29, 2024, BMY announced that the European Commission approved Opdivo in combination with cisplatin and gemcitabine for the first-line treatment of unresectable or metastatic urothelial carcinoma (UC). With this approval, Opdivo became the first concurrent immunotherapy-chemotherapy approved for treating UC in the European Union.

On May 16, 2024, BMY announced that the FDA granted accelerated approval for Breyanzi, a CAR T cell therapy, for treating adults with relapsed or refractory follicular lymphoma (FL). It is also listed in the National Comprehensive Cancer Network Guidelines for B-cell Lymphomas as a therapy for relapsed or refractory FL.

In terms of forward Price/Sales, BMY is trading at 1.87x, 49.2% lower than the industry average of 3.69x. The stock’s forward EV/Sales of 2.90x is 16.2% lower than the industry average of 3.46x.

For the fiscal first quarter that ended March 31, 2024, BMY’s total revenues increased 4.7% year-over-year to $11.87 billion. Its non-GAAP gross profit rose 1.5% from the year-ago quarter to $8.96 billion. As of March 31, 2024, BMY’s total assets amounted to $99.03 billion, compared to $95.16 billion as of December 31, 2023.

Street expects BMY’s fiscal 2025 EPS to increase considerably year-over-year to $6.91. Its revenue for the quarter ending June 30, 2024, is expected to rise 2.4% year-over-year to $11.50 billion. The company surpassed consensus EPS and revenue estimates in three of the trailing four quarters. BMY has gained 2.6% intraday, closing the last trading session at $42.57.

BMY’s strong fundamentals are reflected in its POWR Ratings. It has an overall rating of A, equating to a Strong Buy in our proprietary rating system.

It has an A grade for Value and a B for Growth and Sentiment. It is ranked #9 in the Medical – Pharmaceuticals industry. Get BMY’s Momentum, Stability, and Quality ratings here.

Gilead Sciences, Inc. (GILD)

GILD discovers, develops, and commercializes medicines in the areas of unmet medical need in the U.S., Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for treating HIV/AIDS.

On April 26, 2024, GILD announced that the FDA approved an updated label with additional data reinforcing the safety and efficacy profile of Biktarvy to treat pregnant people with HIV-1 with suppressed viral loads. This update makes Biktarvy the only second-generation integrase strand transfer inhibitor-based single-tablet regimen with in-label clinical trial data.

On March 28, 2024, GILD announced that the FDA approved the supplemental new drug application for Vemlidy 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.

In terms of forward EV/EBITDA, GILD is trading at 10.44x, 20% lower than the industry average of 13.04x. Additionally, the stock’s forward Price/Sales of 2.95x is 20.1% lower than the industry average of 3.69x.

GILD’s revenue for the fiscal first quarter that ended March 31, 2024, amounted to $6.69 billion, up 5.3% year-over-year. Its free cash flow grew 29.3% from the year-ago quarter to $2.11 billion. Moreover, its cash and cash equivalents at end of period stood at $4.72 billion. As of March 31, 2024, GILD’s net accounts receivable amounted to $4.67 billion, compared to $4.66 billion as of December 31, 2023.

For the quarter ending June 30, 2024, GILD’s revenue and EPS are expected to increase 1.6% and 18% year-over-year to $6.70 billion and $1.58, respectively. It surpassed consensus revenue estimates in each of the trailing four quarters. The stock has gained marginally intraday to close the last trading session at $65.25.

GILD’s POWR Ratings reflect its robust prospects. It has an overall A rating, equating to a Strong Buy in our proprietary rating system.

GILD has an A grade for Value and a B for Growth and Quality. Within the Biotech industry, it is ranked first out of 355 stocks. Click here for the additional POWR Ratings of GILD (Momentum, Stability, and Sentiment).

What To Do Next?

43 year investment veteran, Steve Reitmeister, has just released his 2024 market outlook along with trading plan and top 11 picks for the year ahead.

2024 Stock Market Outlook >


ABBV shares were trading at $167.67 per share on Tuesday morning, down $2.79 (-1.64%). Year-to-date, ABBV has gained 10.25%, versus a 12.78% rise in the benchmark S&P 500 index during the same period.


About the Author: Neha Panjwani


From her school days, Neha harbored a profound fascination for finance, a passion that steered her toward a career as an investment analyst following the completion of her bachelor's degree in commerce. Currently enrolled in the CFA program, Neha is dedicated to further enriching her comprehension of investment fundamentals. Neha's primary objective is to aid retail investors in discerning optimal investment opportunities by diligently evaluating crucial aspects of financial instruments, with a primary focus on stocks and ETFs. Her commitment lies in empowering individuals to make informed and strategic investment decisions in the dynamic world of finance. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
ABBVGet RatingGet RatingGet Rating
BMYGet RatingGet RatingGet Rating
GILDGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Bullish or Bearish Stock Set Up?

The S&P 500 (SPY) record highs sounds pretty darn bullish on the surface. Yet as we dig below the surface there are some curious signals that point more Risk Off. This is especially true as we come into the next Fed meeting after a round of data that points to inflation still being too high...only further delaying the first rate cut. What does this all mean for stocks from here? Steve Reitmeister offers his latest views on the market outlook along with a preview of his top picks to stay on step ahead of the market. Read on for more...

Unveiling Adobe (ADBE) Q2 Earnings: What Lies Ahead for Investors?

Software giant Adobe Inc. (ADBE) has released its second-quarter earnings, revealing double-digit growth in both revenue and profits. Yet, concerns arise around the complexities of navigating growth in the face of advancing AI technologies. Let’s analyze ADBE’s recent performance and assess key fundamentals to uncover what lies ahead for investors…

3 AI Stocks to Invest in for the Next Technological Revolution

The AI market is experiencing a significant growth trajectory, driven by widespread application across various industries. Hence, it could be wise to invest in top AI stocks, Alphabet (GOOGL), Meta Platforms (META), and Alibaba Group Holding (BABA) for the next technological revolution. Read more...

Analyzing Broadcom’s (AVGO) Q2 Earnings: Worth Investing?

Driven by a surge in demand for its AI products, Broadcom (AVGO) reported robust earnings in its latest quarterly results, exceeding expectations on both top and bottom lines. However, is the stock’s recent announcement of a 10-for-1 stock split worth investing in? Keep reading to find out…

Stock Alert: Breakout or Fake Out?

The S&P 500 (SPY) officially made new highs this week. Perhaps a reason to celebrate more gains on the way...or perhaps there are signs this move is hollow leading to more downside soon on the way. To help solve this riddle, 44 year investment veteran Steve Reitmeister shares his views along with a trading plan and top picks to stay on the right side of the action. That is what Steve Reitmeister will cover in his latest commentary below. Read on for more...

Read More Stories

More AbbVie Inc. (ABBV) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All ABBV News